NCT05441475 - A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab in HCC Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 30, 2021

Primary Completion Date

July 20, 2024

Study Completion Date

October 10, 2024

Conditions

Hepatocellular Carcinoma

Interventions

DRUG

ABSK-011 180 mg QD combined with atilizumab 1200 mg q3w

All subjects will receive continuous oral administration of absk-011 once a day (QD) or twice a day (bid) with an initial dose of 180 mg, and intravenous infusion (IV) of 1200 mg of atilizumab every 21 days (q3w).

Trial Locations (1)

430030

RECRUITING

Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, Hubei